Hennion & Walsh Asset Management Inc. Has $2.76 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Hennion & Walsh Asset Management Inc. lowered its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.0% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 10,577 shares of the medical research company’s stock after selling 324 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Amgen were worth $2,757,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SignalPoint Asset Management LLC lifted its holdings in Amgen by 10.9% during the 4th quarter. SignalPoint Asset Management LLC now owns 1,358 shares of the medical research company’s stock valued at $354,000 after purchasing an additional 134 shares during the last quarter. StrongBox Wealth LLC raised its position in shares of Amgen by 0.4% in the fourth quarter. StrongBox Wealth LLC now owns 11,649 shares of the medical research company’s stock valued at $3,036,000 after purchasing an additional 42 shares during the period. Flywheel Private Wealth LLC acquired a new stake in shares of Amgen during the 4th quarter worth about $340,000. Rovin Capital UT ADV boosted its holdings in shares of Amgen by 89.1% during the 4th quarter. Rovin Capital UT ADV now owns 1,235 shares of the medical research company’s stock worth $322,000 after buying an additional 582 shares during the period. Finally, Smith Thornton Advisors LLC grew its stake in Amgen by 53.3% in the 4th quarter. Smith Thornton Advisors LLC now owns 1,185 shares of the medical research company’s stock valued at $309,000 after buying an additional 412 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Redburn Partners cut their price objective on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Piper Sandler dropped their price target on Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a report on Thursday, January 2nd. Piper Sandler Companies restated an “overweight” rating and issued a $310.00 price target on shares of Amgen in a research note on Thursday, January 2nd. UBS Group reduced their price target on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday, October 31st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 price target on shares of Amgen in a research note on Tuesday, October 22nd. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $314.91.

Amgen Price Performance

Shares of AMGN opened at $269.43 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The stock has a market cap of $144.83 billion, a PE ratio of 34.50, a PEG ratio of 2.68 and a beta of 0.56. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The business has a 50-day simple moving average of $276.06 and a two-hundred day simple moving average of $307.76.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter in the prior year, the firm posted $4.96 earnings per share. The firm’s revenue was up 23.2% compared to the same quarter last year. Analysts anticipate that Amgen Inc. will post 19.57 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.53%. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.